U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07383441) titled 'Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer' on Jan. 26.
Brief Summary: This phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy alone in treating patients with clear cell renal cell cancer that may have spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started to other places in the body (metastatic). Studies have shown that g...